Alternative polyadenylation of cyclooxygenase-2

被引:70
|
作者
Hall-Pogar, T
Zhang, H
Tian, B
Lutz, CS
机构
[1] Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, New Jersey Med Sch, Newark, NJ 07101 USA
[2] Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Grad Sch Biomed Sci, Newark, NJ 07101 USA
[3] Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Bioinformat Ctr, Newark, NJ 07101 USA
基金
美国国家科学基金会;
关键词
D O I
10.1093/nar/gki544
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A biologically important human gene, cyclo-oxygenase-2 (COX-2), has been proposed to be regulated at many levels. While COX-1 is constitutively expressed in cells, COX-2 is inducible and is upregulated in response to many signals. Since increased transcriptional activity accounts for only part of the upregulation of COX-2, we chose to explore other RNA processing mechanisms in the regulation of this gene. We performed a comprehensive bioinformatics survey, the first of its kind known for human COX-2, which revealed that the human COX-2 gene has alternative polyadenylation (proximal and distal sites) and suggested that use of the alternative polyadenylation signals has tissue specificity. We experimentally established this in HepG2 and HT29 cells. We used an in vivo polyadenylation assay to examine the relative strength of the COX-2 proximal and distal polyadenylation signals, and have shown that the proximal polyadenylation signal is much weaker than the distal one. The efficiency of utilization of many suboptimal mammalian polyadenylation signals is affected by sequence elements located upstream of the AAUAAA, known as upstream efficiency elements (USEs). Here, we used in vivo polyadenylation assays in multiple cell lines to demonstrate that the COX-2 proximal polyadenylation signal contains USEs, mutation of the USEs substantially decreased usage of the proximal signal, and that USE spacing relative to the polyadenylation signal was significant. In addition, mutation of the COX-2 proximal polyadenylation signal to a more optimal sequence enhanced polyadenylation efficiency 3.5-fold. Our data suggest for the first time that alternative polyadenylation of COX-2 is an important post-transcriptional regulatory event.
引用
收藏
页码:2565 / 2579
页数:15
相关论文
共 50 条
  • [21] Selective cyclooxygenase-2 inhibitors
    Prasit, P
    Riendeau, D
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 32, 1997, 32 : 211 - 220
  • [22] Cyclooxygenase-2 in glioblastoma multiforme
    Qiu, Jiange
    Shi, Zhi
    Jiang, Jianxiong
    DRUG DISCOVERY TODAY, 2017, 22 (01) : 148 - 156
  • [23] Update on cyclooxygenase-2 inhibitors
    Harris, Raymond C.
    Breyer, Matthew D.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (02): : 236 - 245
  • [24] Cyclooxygenase-2 in cancer: A review
    Goradel, Nasser Hashemi
    Najafi, Masoud
    Salehi, Eniseh
    Farhood, Bagher
    Mortezaee, Keywan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5683 - 5699
  • [25] Cyclooxygenase-2 and prostate carcinogenesis
    Hussain, T
    Gupta, S
    Mukhtar, H
    CANCER LETTERS, 2003, 191 (02) : 125 - 135
  • [26] Cyclooxygenase-2 and bone resorption
    Pilbeam, CC
    CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, 1998, : 49 - 56
  • [27] Lung cancer and cyclooxygenase-2
    Castelao, JE
    Bart, RD
    DiPerna, CA
    Sievers, EM
    Bremner, RM
    ANNALS OF THORACIC SURGERY, 2003, 76 (04): : 1327 - 1335
  • [28] Cyclooxygenase-2 as a therapeutic target
    J. A. Mitchell
    T. W. Evans
    Inflammation Research, 1998, 47 (Suppl 2) : 88 - 92
  • [29] Selective cyclooxygenase-2 inhibitors
    Golden, BD
    Abramson, SB
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1999, 25 (02) : 359 - +
  • [30] Cyclooxygenase-2: The future is now
    Anil K. Rustgi
    Nature Medicine, 1998, 4 : 773 - 774